ANO10 is a potential prognostic biomarker and correlates with immune infiltration in breast cancer

Several diseases have been linked to the dysfunction of anoctamins. Anoctamins play a wide range of physiological roles, including cell proliferation, migration, epithelial secretion, and calcium-activated chloride chan-nel activity. However, the function of anoctamin 10 (ANO10) in breast cancer is still unclear. ANO10 was highly ex-pressed in bone marrow, blood, skin, adipose tissue, thyroid gland and salivary gland, while ANO10 was expressed at low levels in liver and skeletal muscle. Compared to benign breast lesions, the protein level of ANO10 was lower in malignant breast tumors. However, breast cancer patients with low ANO10 expression have favorable survival outcomes. ANO10 was negatively correlated with the infiltration of memory CD4 T cells, naive B cells, CD8 T cells, chemokines and chemokine receptors. Furthermore, the ANO10 low expression group was more sensitive to certain chemotherapy drugs, including bleomycin, doxorubicin, gemcitabine, mitomycin and etoposide. Altogether, ANO10 is a potential biomarker that can effectively predict the prognosis of breast cancer. Our findings highlight the promis-ing prognostic value and therapeutic target of ANO10 in breast cancer.

Automated summary

The function of ANO10 in breast cancer is still unclear, but its low expression level is associated with malignant breast tumors compared to benign breast lesions. Low ANO10 expression is correlated with favorable survival outcomes and negatively correlated with infiltration of memory CD4 T cells, naive B cells, CD8 T cells, chemokines, and chemokine receptors. Additionally, the ANO10 low expression group is more sensitive to certain chemotherapy drugs. Overall, ANO10 is a potential biomarker that can effectively predict the prognosis of breast cancer and a promising prognostic indicator and therapeutic target in breast cancer treatment.